SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

13 Feb 2025 Evaluate
The revenue zoomed 10.34% to Rs. 16626.80 millions for the quarter ended December 2024 as compared to Rs. 15068.20 millions during the corresponding quarter last year.The Profit  for the quarter ended December 2024 of  Rs. 2675.60  millions  grew by 95.38% from Rs. 1369.40 millions.The company reported a good operating profit of 4285.00 millions compared to 2899.30 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 16626.80 15068.20 10.34 50394.80 46558.20 8.24 61664.60 58146.20 6.05
Other Income 174.10 168.90 3.08 498.00 961.90 -48.23 1112.90 1111.90 0.09
PBIDT 4285.00 2899.30 47.79 12162.40 10152.30 19.80 13226.70 10230.40 29.29
Interest 101.70 272.10 -62.62 468.40 966.10 -51.52 1206.70 439.20 174.75
PBDT 4183.30 2631.70 58.96 11694.00 8795.80 32.95 10686.40 9791.20 9.14
Depreciation 628.10 630.20 -0.33 1867.80 1847.20 1.12 2464.80 2286.30 7.81
PBT 3555.20 2001.50 77.63 9826.20 6948.60 41.41 8221.60 7504.90 9.55
TAX 879.60 632.10 39.16 2668.10 2292.10 16.40 2917.50 2447.90 19.18
Deferred Tax -15.40 11.10 -238.74 18.10 31.10 -41.80 37.40 208.40 -82.05
PAT 2675.60 1369.40 95.38 7158.10 4656.50 53.72 5304.10 5057.00 4.89
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 25.77 19.24 33.94 24.13 21.81 10.68 21.45 17.59 21.91

Ipca Laboratories Share Price

1557.90 -5.80 (-0.37%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×